First results of a dose-escalation study evaluating <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).
Miguel Zugman(City of Hope), Alex Chehrazi-Raffle(City of Hope), Xiaochen Li(City of Hope), Motomichi Takahashi, Sumanta Kumar Pal(City Of Hope National Medical Center), Daniela V. Castro(City of Hope), Peter P. Lee(Moffitt Cancer Center), Hedyeh Ebrahimi(City of Hope), Keehoon Lee(Translational Genomics Research Institute), Thomas P. Parks(Boehringer Ingelheim (United States)), JoAnn Hsu(City of Hope), Nazli Dizman(The University of Texas MD Anderson Cancer Center), Salvador Jaime-Casas(City of Hope), Atsushi Hayashi, Regina Barragan-Carrillo(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Timothy Walter Synold(City of Hope), T. Dorff(City of Hope), Miguel Guzman(City of Hope), Gregory Caporaso(Translational Genomics Research Institute)
Cited by 0
Related Papers
Transcriptional Regulation of the Intercellular Adhesion Molecule-1 Gene by Inflammatory Cytokines in Human Endothelial Cells
|Journal of Biological Chemistry|1995|540
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy
|Journal of Immunotherapy|2002|299
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|184
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
|Clinical Cancer Research|2011|109